Yesterday I had a couple of really good conversations with two Scottish General Practitioners and I asked them about their views on today's medical representatives.
Yesterday I had a couple of really good conversations with two Scottish General Practitioners and I asked them about their views on today's medical representatives. I have collated their comments and summarised them in bullet point form below.
They still did see representatives and when I asked them what was it that made them see these particular reps these were the responses.
It was also interesting to note that both GPs did see some reps whose medicines were not being advocated by the SMC and when I asked why they did agree to see them then they answered ' all of the above'! One of them replied and I quote. "If I think a particular drug is right for my patient then, whilst I respect the SMC recommendations in relation to that drug, I will always justify the use of that particular drug."
So, in conclusion, as regards these particular GPs seeing medical reps they will continue to do so provided the rep is professional, competent, understanding and empathetic and can assist the practice develop in more ways than just promoting their particular medicines.
So maybe if we recruit more effectively, get the 'account management' aspect of the medical representative's role right and we continue to build their skill base beyond selling skills then perhaps we can get access levels increased above the frightfully low levels that are being recorded at present.
blog comments powered by DisqusKevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
The Mobile Health Competition is now closed, but the journey is just beginning for the winning idea.
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs